Elinor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-12-2024
- Paid Up Capital ₹ 3.60 M
as on 15-12-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 22.29%
(FY 2022)
- Profit 27.14%
(FY 2022)
- Ebitda -3.18%
(FY 2022)
- Net Worth 20.84%
(FY 2022)
- Total Assets 1.33%
(FY 2022)
About Elinor Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.60 M, as per Ministry of Corporate Affairs (MCA) records.
Salla Santosh and Gopala Konduru serve as directors at the Company.
- CIN/LLPIN
U24232TG2010PTC071273
- Company No.
071273
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Nov 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elinor Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Salla Santosh  | Director | 19-Nov-2010 | Current |
| Gopala Konduru | Director | 29-Mar-2011 | Current |
Financial Performance of Elinor Pharmaceuticals.
Elinor Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.29% increase. The company also saw a substantial improvement in profitability, with a 27.14% increase in profit. The company's net worth Soared by an impressive increase of 20.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elinor Pharmaceuticals?
In 2022, Elinor Pharmaceuticals had a promoter holding of 66.71% and a public holding of 33.29%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elinor Pharmaceuticals?
Elinor Pharmaceuticals has a workforce of 89 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elinor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elinor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
